key: cord-0705711-8h14zl97
authors: Patel, Tejas K.; Barvaliya, Manish; Kevadiya, Bhavesh D.; Patel, Parvati B.; Bhalla, Hira Lal
title: Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
date: 2020-06-30
journal: J Neuroimmune Pharmacol
DOI: 10.1007/s11481-020-09940-9
sha: a29d7f92220e9a45a1040c7c33c1578d869bfc68
doc_id: 705711
cord_uid: 8h14zl97

nan

The recent retractions of two articles from the Lancet (Mehra et al. 2020a ) and the New England Journal of Medicine (Mehra et al. 2020b ) on the use of hydroxychloroquine has highlighted the needs for increased scrutiny of primary data sources. These retractions have created doubts in the minds of physicians and physician-scientists on therapeutic usages for Corona Virus Disease -2019 (COVID-19) and the tremendous pressure placed on health care providers to find definitive preventive and treatment strategies. Recently we also published a Systematic Review titled "Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review for the Journal of Neuroimmune Pharmacology" ). Our primary aim was to search out whether hydroxychloroquine would reduce the mortality of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We performed the secondary analysis of mortality data from both non randomized controlled trial and retrospective observational studies available in the public domain.

For clarity, independent study results were used in our research. None of the included studies in our systemic review were linked to recent retractions. Indeed, the findings of metaanalysis depend on the credibility of the included studies and data extraction process. We wish to affirm the data extraction and analyses made to the Journal's readership. To meet the ethical standards of publications, we herein share data extraction sheet (Supplementary File 1) and ReVMan software file (Supplementary File 2) of the analyses performed. We also want to state that the findings of our systematic review are preliminary and await further confirmatory data sets. It should only be interpreted in the lights of such limitations.

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. [published online ahead of print

Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19

Does adding of Hydroxychloroquine to the standard care provide any benefit in reducing the mortality among COVID-19 patients?: a systematic review

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations